Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 127   

Articles published

VRX 117.43 -3.09 (-2.56%)
price chart
3 Reasons to Choose Brookfield Asset Management Inc. Over Valeant ...
Brookfield Asset Management (TSX: BAM.A)(NYSE: BAM) and Valeant Pharmaceuticals (TSX: VRX)(NYSE: VRX) are two of Canada's most successful companies.
Related articles »  
Doubts mount about Valeant Pharmaceuticals' tax structures
MONTREAL - The disclosure by Valeant Pharmaceuticals International Inc. that it is under audit by the U.S. Internal Revenue Service is raising further doubts among tax specialists about the future of the Quebec-based drug company's tax strategies ...
Related articles »  
January 2017 Options Now Available For Valeant Pharmaceuticals International ...
Investors in Valeant Pharmaceuticals International Inc (NYSE: VRX) saw new options begin trading today, for the January 2017 expiration.
Related articles »  
Valeant Pharmaceuticals Intl Receives Consensus Recommendation of "Buy ...
On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.00 earnings per share for the current fiscal year. Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical ...
Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility ...
Valeant Pharmaceuticals International, Inc. today announced that the company hosted a ribbon cutting ceremony for the new Bausch + Lomb ULTRA� contact lens manufacturing lines and solar array assembly at the company's Optics Center in Rochester, ...
Related articles »  
Stocks Buzz - Valeant Pharmaceuticals Intl Inc (VRX), Chico's FAS, Inc. (NYSE ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) publicized that its wholly owned affiliate, Valeant Pharmaceuticals International, will redeem all of the outstanding $500.0 million aggregate principal amount of its 6.75% Senior Notes due 2017, CUSIP Nos.
News Review - Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Crown Castle ...
Manhattan, NY- September 16, 2014 - (Techsonian) - Valeant Pharmaceuticals Intl Inc (NYSE:VRX) recently declared that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem all of the outstanding $500.0 million aggregate ...
Related articles »  
Allergan Inc. (AGN) Will Not Succeed in Delaying Stockholders' Special Meeting ...
In a new filing with the U.S. Securities and Exchange Commission, Pershing Square, managed by Bill Ackman, has disclosed its and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) response to a recent announcement by Allergan Inc. (NYSE:AGN) regarding ...
Allergan, Inc. (NYSE:AGN) And Valeant Pharmaceuticals Intl Inc (NYSE:VRX ...  WallStreetPR
Allergan Says Valeant Seeking Hearing on Shareholder Meeting  Bloomberg
Related articles »  
Allergen Vs Valeant: The Battle Continues
Valeant Pharmaceuticals Intl Inc. (VRX) and Bill Ackman continue their fight to take over Allergan, Inc. (AGN). In the latest move, Ackman and Valeant have filed a countersuit against Allergen's lawsuit, which questioned the legality of the duo's ...
Botox-maker Allergan reviews requests to replace board, Valeant eyes takeover  CTV News
Related articles »  
Valeant Pharmaceuticals Intl Receives Consensus Rating of "Buy" from Analysts ...
Finally, analysts at Susquehanna cut their price target on shares of Valeant Pharmaceuticals Intl to $160.00 in a research note on Friday, August 1st.